Embedded Files
Europe Biosimilar Market 2025-2033
According to IMARC Group's report titled "Europe Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Country 2025-2033", the report presents a thorough review featuring the market share, growth, share, trends, and research of the industry.
How Big is the Europe Biosimilar Industry?
The Europe biosimilar market size reached USD 13,864 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 59,733.3 Million by 2033, exhibiting a growth rate (CAGR) of 17.1% during 2025-2033.
Europe Biosimilar Market Trends:
This induces the European market predominantly by the rising demand for affordable treatment options for chronic patients. It has opened up to the increasing availability of biosimilars with the rising incidence of biologic drugs nearing patent expiration, thus spurring market growth. Moreover, the improving healthcare infrastructure in the region is gaining the wider adoption of biosimilars as facilitated by favorable regulatory frameworks. By escalation, the increasing health care expenditure in Europe empowers the patients and providers to consider biosimilars as viable options.
Furthermore, another driver for biosimilar uptake where major expenses are potentially saved without compromising treatment efficacy is inflating overall health expenditures in Europe. This thus promotes the economy. Apart from this, government bodies' growing support to health organizations in biosimilar development is turning as a prominent growth-inducing factor. Also, increasing awareness campaigns on the safety and efficacy of biosimilars will encourage acceptance among healthcare professionals and patients. The growing investments by pharmaceutical industries in biosimilar research and development further stimulate the market and make room for innovation and competition.
For an in-depth analysis, you can refer free sample copy of the report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample
Europe Biosimilar Market Scope and Growth Analysis:
The market scope is expected to widen significantly owing to new therapeutic applications emerging in oncology, immunology, and endocrinology to meet clinical demands. Also, with an increase in the adoption of biosimilars by hospitals, there is new momentum toward their incorporation into mainstream therapy regimens, thus boosting the market even further. Not to mention, it makes all biosimilar drugs very cheaper so that they can create the chance to access most of advanced therapy, especially in emerging economies within Europe. Besides, the strengthened collaborations between different regulatory authorities and the pharmaceutical companies have brought in an efficient pathway for licensing and faster product launches.
The increased number of local manufacturers constitutes another dimension in making the market more diverse, addressing region-specific demands and preferences. The high-speed technological modernization for manufacturing has boosted efficiency in production costs and improved supply chain dynamics. Besides, the confidence of prescribers has been further increased by a greater emphasis on biosimilar interchangeability, adding up to increased market acceptability. Market analysis says that the altering reimbursement policies advocating for biosimilar adoption is also altering the market outlook towards being more favorable for all entities concerning the industry and, subsequently, healthcare systems.
Ask Analyst For Customization: https://www.imarcgroup.com/request?type=report&id=1023&flag=C
By the IMARC Group, the Top Competitive Landscapes Operating in the Industry:
Novartis
Pfizer
Teva
Celltrion
Merck Sharp & Dohme
Samsung Bioepis
Eli Lilly
Accord Healthcare Ltd.
Amgen
Boehringer Ingelheim
Hexal Ag
Apotex
Stada Arzneimittel Ag
Ratiopharm
Mylan
Europe Biosimilar Market Segmentation:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest Europe biosimilar market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.
Breakup by Molecule:
Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Adalimumab
Breakup by Indication:
Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility
Breakup by Manufacturing Type:
In-house Manufacturing
Contract Manufacturing
Breakup by Country:
Italy
Germany
United Kingdom
France
Spain
Rest of Europe
Key highlights of the Report:
Market Performance (2019-2024)
Market Outlook (2025-2033)
COVID-19 Impact on the Market
Porter’s Five Forces Analysis
Strategic Recommendations
Historical, Current and Future Market Trends
Market Drivers and Success Factors
SWOT Analysis
Structure of the Market
Value Chain Analysis
Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Page updated
Google Sites
Report abuse